B of A Securities Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces Price Target of $244
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
B of A Securities analyst Jason Zemansky initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and announces Price Target of $244.
B of A Securities analyst Jason Zemansky initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and announces Price Target of $244.